APA

Stirban A. O., Andjelkovic M., Heise T., Nosek L., Fischer A., Gastaldelli A. & Herz M. (20171023). Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial. : Diabetes, obesity & metabolism.

Chicago

Stirban A O, Andjelkovic M, Heise T, Nosek L, Fischer A, Gastaldelli A and Herz M. 20171023. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial. : Diabetes, obesity & metabolism.

Harvard

Stirban A. O., Andjelkovic M., Heise T., Nosek L., Fischer A., Gastaldelli A. and Herz M. (20171023). Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial. : Diabetes, obesity & metabolism.

MLA

Stirban A O, Andjelkovic M, Heise T, Nosek L, Fischer A, Gastaldelli A and Herz M. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial. : Diabetes, obesity & metabolism. 20171023.